GW Pharmaceuticals tests epilepsy drug in man as FDA softens stance

A.B. | ShareCast | 18 Sep, 2013 11:09 - Updated: 11:59 | | |

Drugs

Cannabis-derived drug developer GW Pharmaceuticals has begun human trials of its epilepsy treatment.

The AIM- and Nasdaq-listed company said the novel drug candidate, currently named GWP42006, was one of its most promising and looked to have significantly fewer side effects than currently approved anti-epileptic drugs.

Dr. Stephen Wright, Director of Research and Development at the company said advancing GWP42006 to a first dose in man was a significant milestone in the development of this candidate.

“The decision to progress into Phase 1 follows several years of highly promising pre-clinical research," he added.

"We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need."

Research with the Reading School of Pharmacy in Buckinghamshire has shown that GWP42006 not only exerts significant ability to treat seizures in a wide range of preclinical models of seizure and epilepsy, but is also better tolerated by patients compared to existing anti-epileptic drugs.

The company has been encouraged by recent interest in its products in the US. That arose after the pharmaceutical regulator, the Food and Drug Administration [FDA], allowed US epilepsy specialists and patient organizations to carry out treatment on a small number of pediatric epilepsy patients with a cannabidiol [CBD] formulation supplied by GW. These activities may generate initial evidence to add CBD as a further pipeline candidate for clinical evaluation in epilepsy.

Recent third quarter showed net cash of $66.3m thanks to a US IPO in May that raised $30.4m.

Shares in GWP were up 1.4% to 72p at 11:12 on Wednesday.

OH

More news

12:28 Europe midday: Stocks dip into the red ahead of the Wall Street open

The main European equity gauges were holding in the red come midday despite some positive news out of the periphery.

12:33 Tesco results live: comment, reaction and analysis

Welcome to our rolling coverage of Tesco's results this morning:

12:07 Market overview: UK retail sales weakness only temporary, says EY ITEM Club

1208: The EY ITEM Club has said that the weakness in September's retail sales data in the UK is "likely to prove temporary". However, it expects the quarterly slowdown in retail sales to be reflected in the Q3 GDP figures due out tomorrow, which it forecasts will show growth slowing from 0.9% to 0.8%.

12:04 Broker tips: Rio Tinto, Tullow Oil, Foxtons

Investec hailed Thursday's announcement by mining group Rio Tinto that it has decided to extend the tenure of its chief executive officer (CEO) Sam Walsh and also its chief financial officer, saying it provides certainty for shareholders.

12:01 Westhouse highlights buying opportunity at Tullow despite mixed Kenyan update

Tullow Oil's share price dropped sharply on Thursday after the company reported a mixed exploration and appraisal update on Kenyan operations, though analysts at Westhouse Securities recommend investors to use this weakness as a buying opportunity.

12:00 Support and resistance levels for the main equity benchmark

The following are the technical support and resistance levels for the major global equity benchmarks.

11:55 NHS unveils drastic overhaul proposals in Five Year Forward View report

The NHS has laid out radical new proposals as it unveiled for the first time a clear plan on how it intends to close the £30bn funding gap expected to open up by 2020.

11:50 Inchcape reports 'strong' third quarter performance, despite currency headwinds

Automotive retail and services company Inchcape reported a strong third quarter performance, with revenue up 10.6% year-on-year at £1.697bn at constant currency.

11:49 Support and resistance levels for the main currency pairs

The following are the technical support and resistance levels for Forex trading.

11:47 Foxtons still a 'buy' despite profit warning, says Numis

Investors of Foxtons shouldn't be deterred by a profit warning from the estate agency group, says Numis Securities, which maintained its 'buy' rating after a sell-off in the shares on Thursday.

Advertising

HIGHLIGHTS

NHS unveils drastic overhaul proposals in Five Year Forward View report

The NHS has laid out radical new proposals as it unveiled for the first time a clear plan on how it intends to close the £30bn funding gap expected to open up by 2020.

VIDEOS

EUR/USD: continues its clearly bearish trend
REGISTER NOW!